A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Symptoms, Exercise Function and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril; Valsartan
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARALLAX
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Jan 2018 Planned primary completion date changed from 11 Sep 2019 to 4 Dec 2019.
- 29 Aug 2017 Status changed from not yet recruiting to recruiting.
- 30 Jun 2017 Planned initiation date changed from 15 Jun 2017 to 8 Sep 2017.